2022 Bipolar disorder Personality disorders 
Psychiatric Times
JUNE 27, 2025
Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now! Related Videos Related Content Advertisement June 13th 2025 Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score John J.
Psychiatric Times
JULY 1, 2025
children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. National Center for Health Statistics; Centers for Disease Control and Prevention. September 2024. Accessed July 1, 2025. Danielson ML, Claussen AH, Bitsko RH, et al. ADHD prevalence among U.S. J Clin Child Adolesc Psychol. 2024;53(3):343-360.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 23, 2025
News Media Around the Practice Between the Lines PsychView Expert Perspectives Case-Based Psych Perspectives Clinical Case Collective Dialogues Payer-Provider Perspective Slideshows Videos Viewpoints Conferences Conference Coverage Conference Listing Publication Psychiatric Times Job Board CME/CE Partners Editorial Resources Clinical Consult Clinical (..)
Psychiatric Times
JUNE 13, 2025
She has been on an antipsychotic medication to treat her bipolar disorder for 10 years, resulting in stability of mood symptoms that were previously poorly controlled. In 2022, a panel of TD experts developed a standardized tool that could be utilized easily in a clinical setting to assess TD’s impact on functioning in various domains.
Psychiatric Times
JUNE 12, 2025
link] Related Videos Related Content Advertisement May 29th 2025 Treatment Comparison: Somnolence/Sedation With Dopamine Partial Agonists vs D2 Receptor Antagonists Leah Kuntz April 9th 2022 Here's to a Psychedelic Revolution Amir Inamdar MBBS, DNB (Psych), MFPM May 23rd 2025 Looking Ahead to the ASCP Annual Meeting With Joseph F.
Psychiatric Times
JULY 2, 2025
News Media Peer Exchange Case-Based Psych Perspectives Clinical Case Collective Insights Peers & Perspectives Slideshows Videos Conferences Conference Coverage Conference Listing Publication Psychiatric Times Job Board CME/CE Partners Editorial Resources Between the Lines Expert Perspectives Clinical Consult Clinical Scales Interactive Tools Partner (..)
Psychiatric Times
JULY 11, 2025
FDA approval in 2022 for treating major depressive disorder was based on 3 pivotal clinical trails: - ASCEND 2 , in which it demonstrated separation from bupropion and rapid effects across 6 weeks - GEMINI, a phase 3 randomized, double-blind, placebo-conrolled trial in which it demonstrated a 16.6 May 19, 2022. January 21, 2025.
Expert insights. Personalized for you.
88 
Let's personalize your content